Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study

Abstract

Background Membranous nephropathy (MN) is mainly classified into idiopathic MN (iMN) and secondary MN in etiology. In recent years, a new kind of membranous nephropathy, atypical membranous nephropathy (aMN) which shows “full house” in immunofluorescence but without definite etiology was paid more attention. In a single center cohort, the renal outcomes of iMN and aMN were compared. Methods iMN and aMN patients were selected from renal pathology databank from January 2006 to December 2015. Patients’ demographics, laboratory values, induction regimens and patients’ responses were recorded. Specially, creatinine, eGFR, albumin and 24\xa0h urinary protein excretion were recorded at 6th month after the induction of immunosuppressive (IS) treatment and at the end of follow up. Complete proteinuria remission was defined as urinary protein\u2009<\u20090.3\xa0g/d, partial proteinuria remission was defined as urinary protein between 0.3\xa0g/d\u2009~\u20093.5\xa0g/d and decreased\u2009>\u200950\u2009% from the baseline. The primary outcome was worsening renal function, defined as a 30\u2009% or more decrease in eGFR or end-stage renal disease (eGFR\u2009<\u200915ml/min/1.73m 2 ). COX proportional hazard models were used to test if aMN was a risk factor of worsening renal function compared with iMN. Results There were 298 patients diagnosed with MN and followed in our center for 1 year or more, including 145 iMN patients with an average follow-up time of 4.5\u2009±\u20092.6 years, and 153 aMN patients with 4.1\u2009±\u20092.0 years ( p \u2009=\u20090.109). The average age of iMN patients was older than aMN patients (56.1\u2009±\u200912.2 versus 47.2\u2009±\u200916.2 years old, p \u2009<\u20090.001). There were 99 iMN patients and 105 aMN patients with nephrotic range proteinuria and without previous immunosuppressive treatment. 93 (93.9\u2009%) and 95 (90.5\u2009%) patients underwent immunosuppressive treatment in iMN and aMN group, and there was no significant difference of the overall proteinuria remission rates at 6th month (59.1\u2009% vs. 52.0\u2009%, p \u2009=\u20090.334) and endpoint (73.7\u2009% vs. 69.5\u2009%, p \u2009=\u20090.505) between the two groups. 25 (25.3\u2009%) patients in iMN group and 21 (20.0\u2009%) patients in aMN group reached primary endpoint (X 2 \u2009=\u20090.056, p \u2009=\u20090.812). Multivariate COX regression showed that after demographics, baseline laboratory values and remission status at 6th month were adjusted, aMN group had similar renal outcome compared with iMN group, the HR of primary outcome was 0.735 (95\u2009% CI 0.360\u2009~\u20091.503, p \u2009=\u20090.399). Conclusions The proteinuria remission rates and renal outcomes were similar in iMN and aMN patients after covariables were adjusted.